Recruiting

Observational Study

Sponsor:

Henry M. Jackson Foundation for the Advancement of Military Medicine

Code:

NCT07652580

Conditions

Non-Hodgkin Lymphoma

Lymphoma Non-Hodgkin

B-cell Lymphoma

Immune Dysregulation

Eligibility Criteria

Sex: All

Age: 4+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether specific exposures and germline variants are associated with B-cell NHL subtype, immune dysfunction, and clinical outcomes. Participants will complete exposure and medical-history surveys, provide biospecimens for immune and genomic testing, and may be followed annually for up to 3 years.

Conditions

Non-Hodgkin Lymphoma

Lymphoma Non-Hodgkin

B-cell Lymphoma

Immune Dysregulation

Study ID

NCT07652580

Start date

May 1, 2025

Status verified date

Sep, 2026

Completion date

May 1, 2028

Anticipated

Primary completion date

May 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 4+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 4 years old and older with a clinical diagnosis of B-cell NHL.
  • Must be willing to undergo phlebotomy and/or skin punch biopsy.
  • Must be willing to undergo whole genome sequencing, which includes return of primary and secondary findings.

Exclusion Criteria:

  • Has any condition that, in the opinion of the Principal Investigator, contraindicates participation in this study. Examples of situation that may contraindicate participation include but are not limited to a) some cases of cerebral vascular accidents where an individual no longer has the capacity to make their own medical decisions and a conservator or responsible family member is not available and b) an individual has active suicidal ideation and is a danger to themselves at the time of enrollment.
  • Does not have access to health care and primary care clinician.
  • Actively undergoing induction treatment for NHL.

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Cohort 1

Active duty service members (ADSMs) and other Military Health System (MHS) beneficiaries who have a history of B-cell non-Hodgkin Lymphoma (NHL) and have achieved clinical remission.

Cohort 2

ADSMs and other MHS beneficiaries ages 18 and older who are newly diagnosed that is untreated or NHL that has been previously treated.

Cohort 3

Other MHS beneficiaries ages 4-17 who are newly diagnosed with B-cell NHL or are untreated.

Primary outcome measure

  • Aim 1: Characterize occupational exposures and their impact on health outcomes and immune health of ADSMs and other MHS beneficiaries with B-cell NHL. [ Time Frame: 3 years ]
  • Aim 2: Identify and interpret germline variants in ADSMs and other MHS beneficiaries with B-cell NHL. [ Time Frame: 3 years ]
  • Aim 3: Create a comprehensive database and biorepository of ADSMs and other MHS beneficiaries with B-cell NHL. [ Time Frame: 3 years ]

Central Contacts and Locations

Central contacts

Christin B. Destefano, MD, Lt Col, MC, USAF

(301) 295-3190christin.destefano@usuhs.edu

W. Grant Day, MD, LCDR, MC, USN

(757) 953-2194william.g.day26.mil@health.mil

Locations

Walter Reed National Military Medical Center

Recruiting

Bethesda, Maryland, United States, 20814

Contacts

Christin B Destefano

(301) 295-3190christin.destefano@usuhs.edu

Annika Hamann, RN, BSN, BS

(301) 295-4198annika.hamann.ctr@usuhs.edu

Principal Investigator:

Jeremy Perkins, MD, FACP, COL, US Army (ret)

More Information

Sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Keywords

  • Immunodeficiency
  • Lymphoma
  • Exposure
  • Genetics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Henry M. Jackson Foundation for the Advancement of Military Medicine on 2026-09-03.